Epic & Msn data
| Epic |
YMBA |
| Time: |
07:35:15 |
| Mid Price: |
32.50 |
| Change Today: |
0.00
|
| Change % Today: |
0.00 |
| Fifty Two Week High: |
50.00 |
| Fifty Two Week Low: |
16.50 |
| Market Capital: |
16.49 |
Period & price data
| Period |
Price |
| Now: |
32.50 |
| 3 Months ago: |
28.00 |
| 6 Months ago: |
|
| 1 Year ago: |
50.00 |
Additional information
| Additional |
Information |
| Market: |
TSX, AIM |
| Sector: |
Pharmaceuticals |
| Epic: |
YMBA |
| News: |
Latest news |
| Web Site: |
YM Biosciences |
| Other Articles: |
|
Thursday July 02, 11:10Kalahari Minerals reports 34% increase in uranium resource at Rossing South
Ambrian Capital summed up today’s news perfectly, noting that the resource estimate released today was not only ahead of expectations, but was further buoyed by the increase in grade.
FULL ARTICLE ►
Wednesday July 01, 01:55Forte Energy delivers maiden uranium resource at Firawa Project in Guinea
Forte energy has delivered a maiden JORC Compliant resource at Firawa Uranium Project in Guinea, West Africa.
FULL ARTICLE ►
YM BioSciences is engaged in the licensing and commercialization of drug products and technologies from original research.
The Company is advancing two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer, and AeroLEF, an inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.
Its products in clinical development target solid tumors, including colorectal, prostate, head and neck, breast, pancreatic, esophageal, specific types of brain tumors and acute pain, including cancer pain.
YM Biosciences’ Nimotuzamab selected for Phase III trial by Singapore
YM BioSciences Inc said the National Cancer Centre of Singapore (NCCS) has selected nimotuzumab, its epidermal growth factor receptor -targeting antibody, for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck.
The NCCS stated that it selected nimotuzumab because of its reported preferential safety profile compared with other EGFR-targeting cancer drugs, the oncology group said. The trial is sponsored by the NCCS in collaboration with Innogene Kalbiotech Pte Ltd, YM's licensee for nimotuzumab for the region.
The NCCS is the lead cancer centre coordinating this clinical trial, which will involve approximately 22 institutions from 12 countries worldwide.
The primary endpoint for this study is two-year and five-year disease-free survival; the secondary endpoint is two-year and five-year overall survival.
Register here to be notified of future YM Biosciences articles.
Investors interested in YM Biosciences recently viewed
No investment advice
The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
